Inhibition of Transformation by Levodopa-Carbidopa in Lymphocytes Derived From Patients With Melanoma

This publication has 14 references indexed in Scilit:

• Vitiligo-related pigment cell differentiation antigens are expressed on malignant melanoma cells following phenotypic reversion induced by contact inhibitory factor
  Differentiation, 1985
• Inhibition of ribonucleotide reductase by antitumor agents related to levodopa and dopamine
  Biochemical Pharmacology, 1985
• 3,4-Dihydroxybenzylamine: An Improved Dopamine Analog Cytotoxic for Melanoma Cells in Part Through Oxidation Products Inhibitory to DNA Polymerase
  Journal of Investigative Dermatology, 1983
• Herpesviruses and Parkinsonism
  Archives of Neurology, 1981
• Methyldopa Inhibition of Suppressor-Lymphocyte Function
  New England Journal of Medicine, 1980
• 3,4-Dihydroxybenzylamine: A Dopamine Analog With Enhanced Antitumor Activity Against B16 Melanoma
  JNCI Journal of the National Cancer Institute, 1979
• Levodopa therapy and malignant melanoma
  JAMA, 1978
• L-Dopa: Selective Toxicity for Melanoma Cells in Vitro
  Science, 1977
• Differentiation between B cells, T cells, and histiocytes in melanocytic lesions: Primary and metastatic melanoma and halo and giant pigmented nevi
  Clinical Immunology and Immunopathology, 1975
• Clinical and Histologic Correlation of Melanoma Regression After Intralesional BCG Therapy: A Case Report2
  JNCI Journal of the National Cancer Institute, 1974